We are making progress stopping cancer through research. We hear about new drugs and therapies on a regular basis, but we have a long way to go. Lung, prostate and colon-rectal cancers are the most dangerous in men, and lung, breast and colon-rectal cancers are the most dangerous for women, according to the American Cancer Society.
About 30 years ago Newsweek devoted an entire issue to the topic of Cancer. In the introduction to the issue they made the point that we will never see “a cure for cancer”, because, unlike many other diseases like heart, kidney, liver diseases and diabetes, cancer is actually a family of diseases. And the family is very diverse. While some cancers have known cures, others remain challenging. One important element toward developing a cure for a given type of cancer is to fully understand the conditions and processes that lead to its development, and that takes basic research. The kind that public and private universities do so well. Continue reading One Goal: End Cancer.→
I really enjoy this time of year because business demands usually slow down enough to allow for me to catch up on some things I have neglected, review the year and do some planning for the coming year. I always take time to backup my computers and clean out my email. I do a lot of introspective thinking during the last two weeks of the year, and I normally like to do some writing that is way outside my normal fare. This year I may not have time for some of that because we plan to spend a lot of time with our family. I hope you are able to do that too.
When I was in sixth grade at Lincoln Elementary School in Galva, Illinois, the town built a swimming pool at a new park that was within sight of the school. My friends and I could not believe our luck. In the entire history of the town, nothing as big had ever happened (well, for sixth graders anyway). When the grand opening was scheduled for the day school was let out for the summer, we laid our plans to be the first in line. That’s just what we did. We checked in on the first day and did not leave until the day it closed at the end of the summer. We had so much fun!
I missed my self-imposed Monday deadline for an RxTrace essay this week because I am still recovering from the Pelotonia cancer research fundraiser bike ride that I participated in over the weekend. This year I roused the necessary donations, plus my own contributions, to be able to ride the full 180 miles over the two day event.
“Just because studies have found that men have a nearly 50 percent chance of developing cancer in their lifetimes doesn’t mean that your risk, if you’re a man, is 50 percent. Your individual risk is based on many different factors, such as your age and habits, your family history of cancer, and the environment in which you live.”
Well said. I would add that it also greatly depends on if you, or someone close to you, uses tobacco or not. The point is, some of us have a much lower risk of developing cancer and others have a much higher risk than these averages indicate.
I received news last night that my friend and co-worker, Ivan Shen, passed away on Sunday after losing a five month battle with cancer. During his career Ivan worked for serialization and pedigree companies including Oat Systems, Reva Systems and SupplyScape (now TraceLink). Many RxTrace subscribers are current or former co-workers or former customers of Ivan. Continue reading Yifan “Ivan” Shen (1962–2010)→
…a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance
DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of Dirk Rodgers. The material contained in RxTrace is not legal advice. Dirk Rodgers is not a lawyer. The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating the positions of any company, organization or individual other than Dirk Rodgers.